Harrow, Inc. Current Liabilities
Harrow, Inc. (HROW) had Current Liabilities of $102.17 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-10
- 2026-06-30: Liabilities, Current $102.17M.
- 2026-03-31: Liabilities, Current $91.44M.
- 2025-12-31: Liabilities, Current $96.30M.
- 2025-09-30: Liabilities, Current $65.40M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $102.17M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $91.44M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | $96.30M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $65.40M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $248.88M 10-Q · filed 2025-08-11 | |
| 2025-03-31 | $186.99M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $91.34M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $95.00M 10-Q · filed 2024-11-14 | |
| 2024-06-30 | $53.55M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $41.75M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $49.34M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $19.03M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $23.01M 10-Q · filed 2023-08-09 | |
| 2023-03-31 | $17.71M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $18.63M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $18.37M 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $12.92M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $9.18M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $9.72M 10-K · filed 2023-03-23 | |
| 2021-09-30 | $10.48M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $8.14M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $10.07M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $10.80M 10-K · filed 2022-03-10 | |
| 2020-09-30 | $13.78M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $13.08M 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $13.22M 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $12.28M 10-K · filed 2021-03-08 | |
| 2019-09-30 | $11.43M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $9.86M 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $11.21M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $11.90M 10-K · filed 2020-03-13 | |
| 2018-09-30 | $10.37M 10-Q · filed 2018-11-13 | |
| 2018-06-30 | $8.16M 10-Q · filed 2018-08-06 | |
| 2018-03-31 | $5.90M 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $5.77M 10-K · filed 2019-03-12 | |
| 2017-09-30 | $6.05M 10-Q · filed 2017-11-14 | |
| 2017-06-30 | $5.52M 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $11.79M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $9.90M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $5.78M 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $5.33M 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $5.67M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | $5.37M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $3.74M 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $2.67M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | $2.24M 10-Q · filed 2015-05-13 | |
| 2014-12-31 | $1.56M 10-K · filed 2016-03-23 | $1.56M 10-K · filed 2015-03-12 |
| 2014-09-30 | $1.58M 10-Q · filed 2014-11-12 | |
| 2014-06-30 | $1.34M 10-Q · filed 2014-08-13 | |
| 2014-03-31 | $655.47K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | $650.63K 10-K · filed 2015-03-12 | |
| 2013-09-30 | $1.06M 10-Q · filed 2013-11-06 | |
| 2013-06-30 | $1.11M 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $848.55K 10-Q · filed 2013-05-08 | |
| 2012-12-31 | $709.56K 10-K · filed 2014-03-28 | |
| 2012-09-30 | $669.84K 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $491.20K 10-Q · filed 2012-08-14 | |
| 2012-03-31 | $930.50K 10-Q · filed 2012-05-10 | |
| 2011-12-31 | $1.86M 10-K · filed 2013-03-18 | |
| 2011-09-30 | $1.65M 10-Q · filed 2012-02-23 | |
| 2011-06-30 | $1.60M 10-Q · filed 2012-02-23 | |
| 2010-12-31 | $335.04K 10-Q · filed 2012-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |